Skip to Main Content
×
Quiver Logo Get a Free Trial on Quiver Premium Today!
Back to News

Heron Therapeutics Q2 Revenue Rises To $37.7 Million

None

Heron Therapeutics (HRTX) reported second-quarter 2026 net revenue of $37.7 million, up 9% from the first quarter of 2026 and up 1.3% from $37.2 million a year earlier.

The company posted a second-quarter net loss of $5.5 million, or $0.03 per basic and diluted share. Heron also said it withdrew its previously issued full-year 2026 guidance and amended its credit facility with Hercules Capital.

  • Total net revenue for the three months ended June 30, 2026 was $37.7 million.
  • Acute Care net revenue rose 43.9% year over year to $15.3 million.
  • ZYNRELEF net revenue grew 35.0% year over year to $11.1 million.
  • APONVIE net revenue grew 73.6% year over year to $4.3 million.
  • Oncology net revenue was $22.3 million, down 15.9% year over year.
  • Cash, cash equivalents and short-term investments totaled $42.7 million at quarter end.
  • Heron withdrew full-year 2026 guidance for net product sales and Adjusted EBITDA.

$HRTX Hedge Fund Activity

We have seen 69 institutional investors add shares of $HRTX stock to their portfolio, and 78 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

Add Quiver Quantitative to your preferred sources on Google Google News Logo

Suggested Articles